CN111603552A - 一种抗衰老组合物及其应用 - Google Patents
一种抗衰老组合物及其应用 Download PDFInfo
- Publication number
- CN111603552A CN111603552A CN202010628553.7A CN202010628553A CN111603552A CN 111603552 A CN111603552 A CN 111603552A CN 202010628553 A CN202010628553 A CN 202010628553A CN 111603552 A CN111603552 A CN 111603552A
- Authority
- CN
- China
- Prior art keywords
- parts
- aging
- collagen peptide
- aging composition
- giant salamander
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 102000008186 Collagen Human genes 0.000 claims abstract description 29
- 108010035532 Collagen Proteins 0.000 claims abstract description 29
- 229920001436 collagen Polymers 0.000 claims abstract description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 241000157862 Dicamptodontidae Species 0.000 claims abstract description 25
- -1 compound amino acid Chemical class 0.000 claims abstract description 19
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims abstract description 16
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims abstract description 16
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930192334 Auxin Natural products 0.000 claims abstract description 13
- 239000002363 auxin Substances 0.000 claims abstract description 13
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 9
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 9
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims abstract description 7
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims abstract description 7
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims description 37
- 239000007924 injection Substances 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 229940075582 sorbic acid Drugs 0.000 claims description 11
- 235000010199 sorbic acid Nutrition 0.000 claims description 11
- 239000004334 sorbic acid Substances 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000000829 suppository Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 14
- 230000008439 repair process Effects 0.000 abstract description 5
- 230000037149 energy metabolism Effects 0.000 abstract description 4
- 230000002431 foraging effect Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 230000011506 response to oxidative stress Effects 0.000 abstract description 3
- 230000003938 response to stress Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 230000002792 vascular Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000037303 wrinkles Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005971 DNA damage repair Effects 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010037867 Rash macular Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
本发明公开了一种抗衰老组合物及其应用,所述抗衰老组合物,包括如下重量份的组分:NMN 5~10份、大鲵胶原蛋白肽3~6份、人参皂苷Rg1 1~2份、SOD 2~3份、复合氨基酸1~2份、hgh生长素1~2份和淫羊藿苷2~3份;本发明组合物中NMN能够激活机体能量代谢,改善血管应激反应,能够为衰老细胞补充能量,刺激各衰老组织的新城代谢和修复,延长细胞寿命;再通过与大鲵胶原蛋白肽、复合氨基酸的复配,能够更好的促进衰老组织中各种蛋白的再生和修复,使得衰老组织恢复正常,此外,大鲵胶原蛋白肽和SOD能够清除自由基,调节氧化应激反应,再加以人参皂苷Rg1和淫羊藿苷调节机体免疫力、改善各器官功能,实现从内到外改善机体,达到更好的抗衰老效果。
Description
技术领域
本发明涉及组合物技术领域,具体涉及一种抗衰老组合物及其应用。
背景技术
随着生活水平的提高,人们对身体健康越来越重视,然而,衰老是任何生命过程中的必然规律,但延缓衰老的速度,延长寿命已经成为可能;关于衰老机制众说纷纭,例如,自由基学说,免疫机能退化学说,蛋白质合成差错积累学说、基因调控学说、DNA损伤修复学说等等。然而,皮肤衰老是机体衰老的一部分,表现为皮肤松弛、光泽变暗、弹性下降、褶皱等。
目前,应用于抗衰老的产品并不多,现有康帅老产品大多以食品、中药组合物等口服药物为主,但是效果并不理想;然而有些产品为了达到一定的抗衰老效果,增加大量工业抗氧化成分,虽然见效快,但长时间使用对人体会造成损伤;此外,现有抗衰老产品大多通过口服治疗,然后口服的抗衰老产品在经过人体消化系统时,人体消化系统与药物中的有效成进行反应,造成有效成分的损失,影响治疗效果。
发明内容
本发明的第一目的在于提供一种抗衰老组合物,该组合物通过各原料的组合能够快速充分被人体肠道吸收,并起到激活机体能量代谢、促进DNA损伤修复、胶原蛋白的合成、提高抗氧化酶活性以及清除自由基作用,进而达到延长细胞寿命、修复衰老组织以及延缓衰老的效果。
为了实现本发明的上述目的,特采用以下技术方案:
本发明第一方面提供一种抗衰老组合物,所述抗衰老组合物包括如下重量份的组分:
NMN 5~10份、大鲵胶原蛋白肽3~6份、人参皂苷Rg1 1~2份、SOD 2~3份、复合氨基酸1~2份、hgh生长素1~2份和淫羊藿苷2~3份。
本发明组合物中NMN能够激活机体能量代谢,改善血管应激反应,能够为衰老细胞补充能量,刺激各衰老组织的新陈代谢和修复,延长细胞寿命;再通过与大鲵胶原蛋白肽、复合氨基酸以及hgh生长素的复配,能够更好的促进衰老组织中各种蛋白的再生和修复,使得衰老组织恢复正常,此外,大鲵胶原蛋白肽和SOD能够清除自由基,调节氧化应激反应,再加以人参皂苷Rg1和淫羊藿苷调节机体免疫力、改善各器官功能,实现从内到外改善机体,达到更好的抗衰老效果。
经研究表明,本发明上述组合物还具有改善睡眠、缓解疲劳、降低脂肪塑身紧致以及缓解肌肉酸痛的功效;并对糖尿病、帕金森以及老年痴呆具有一定的改善作用。
优选地,所述抗衰老组合物包括如下重量份的组分:
NMN 8份、大鲵胶原蛋白肽5份、人参皂苷Rg1 1.5份、SOD 2.5份、复合氨基酸1.5份、hgh生长素1.5份和淫羊藿苷2.5份。
通过对各原料的具体用量的限定,能够促进各原料之间的相互作用,提高组合物的整体疗效。
优选地,所述组分还包括山梨酸0.2~0.5份和甘露醇0.2~0.6份;优选地,山梨酸0.3份和甘露醇0.5份。
通过山梨酸和甘露醇的添加,能够提高组合物中各物质的稳定性,以及防止肠道内微生物对组合物有效成分的影响。
优选地,所述大鲵胶原蛋白肽的分子量范围为800~1200道尔顿。
优选地,每份所述复合氨基酸包括天冬氨酸6份、谷氨酸8份、丝氨酸0.1份、甘氨酸0.8份、苏氨酸7份、精氨酸5份、脯氨酸5份、丙氨酸3份、缬氨酸3份、蛋氨酸2份和胱氨酸1份。
本发明第二方面提供一种上述抗衰老组合物在制备抗衰老的药物、营养品或保健品中的应用。
本发明第三方面提供一种通过直肠给药达到抗衰老作用的注射剂,所述注射剂包括上述抗衰老组合物和生理盐水,所述注射剂中抗衰老组合物质量含量为20~30%。
本发明通过选择直肠给药的方式,能够更好的促进各组分的吸收,利于提高上述组合物的整体效果。
本发明第四方面提供一种通过直肠给药达到抗衰老作用的栓剂,所述栓剂包括上述抗衰老组合物和药学上可接受的辅料;
所述辅料质量含量为70~80%。
优选地,所述辅料为甘油明胶或聚乙二醇。
本发明第五方面还提供一种上述栓剂的制备方法,所述制备方法包括如下步骤:
将山梨酸和辅料按照比例混合加热;
将混合物冷却至38~42℃,再加入NMN、大鲵胶原蛋白肽、人参皂苷Rg1、SOD、复合氨基酸、甘露醇、hgh生长素和淫羊藿苷;
随后,进行灌模、冷却、成型、脱模和包装。
上述制备方法制备得到的栓剂,能够防止有效成分在直肠的损失,提高有效成分的吸收利用率,达到更好的抗衰老效果。
与现有技术相比,本发明的有益效果至少包括:
本发明组合物中NMN能够激活机体能量代谢,改善血管应激反应,能够为衰老细胞补充能量,刺激各衰老组织的新城代谢和修复,延长细胞寿命;再通过与大鲵胶原蛋白肽、复合氨基酸以及hgh生长素的复配,能够更好的促进衰老组织中各种蛋白的再生和修复,使得衰老组织恢复正常,此外,大鲵胶原蛋白肽和SOD能够清除自由基,调节氧化应激反应,再加以人参皂苷Rg1和淫羊藿苷调节机体免疫力、改善各器官功能,实现从内到外改善机体,达到更好的抗衰老效果。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍。在所有附图中,类似的元件或部分一般由类似的附图标记标识。附图中,各元件或部分并不一定按照实际的比例绘制。
图1为本发明受试者1中受试者的用药前后的对比图;
图2为本发明受试者2中受试者的用药前后的对比图;
图3为本发明受试者3中受试者的用药前后的对比图。
具体实施方式
下面将结合附图对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚地说明本发明的技术方案,因此只作为示例,而不能以此来限制本发明的保护范围。
需要注意的是,除非另有说明,本申请使用的技术术语或者科学术语应当为本发明所属领域技术人员所理解的通常意义。
各实施例采用的原料如下:
大鲵胶原蛋白肽:按照专利申请号为202010159309.0中实施例1中制备方法制备得到胶原蛋白肽,从中截留分子量为800~1200道尔顿的胶原蛋白肽即可。
其他组分均可通过普通市购得到。
实施例1
本实施例为一种抗衰老组合物,该抗衰老组合物包括如下重量份的组分:
NMN 5份、大鲵胶原蛋白肽6份、人参皂苷Rg1 2份、SOD 2份、复合氨基酸1份、hgh生长素1份、淫羊藿苷3份、山梨酸0.2份和甘露醇0.6份,其中:
每份复合氨基酸包括天冬氨酸6份、谷氨酸8份、丝氨酸0.1份、甘氨酸0.8份、苏氨酸7份、精氨酸5份、脯氨酸5份、丙氨酸3份、缬氨酸3份、蛋氨酸2份和胱氨酸1份;
大鲵胶原蛋白肽的分子量范围为800~1200道尔顿。
实施例2
本实施例为一种抗衰老组合物,该抗衰老组合物包括如下重量份的组分:
NMN 10份、大鲵胶原蛋白肽3份、人参皂苷Rg1 1份、SOD 3份、复合氨基酸2份、hgh生长素2份、淫羊藿苷2份、山梨酸0.5份和甘露醇0.2份,其中:
每份复合氨基酸包括天冬氨酸6份、谷氨酸8份、丝氨酸0.1份、甘氨酸0.8份、苏氨酸7份、精氨酸5份、脯氨酸5份、丙氨酸3份、缬氨酸3份、蛋氨酸2份和胱氨酸1份;
大鲵胶原蛋白肽的分子量范围为800~1200道尔顿。
实施例3
本实施例为一种抗衰老组合物,该抗衰老组合物包括如下重量份的组分:
NMN 8份、大鲵胶原蛋白肽5份、人参皂苷Rg1 1.5份、SOD 2.5份、复合氨基酸1.5份、hgh生长素1.5份、淫羊藿苷2.5份、山梨酸0.3份和甘露醇0.5份,其中:
每份复合氨基酸包括天冬氨酸6份、谷氨酸8份、丝氨酸0.1份、甘氨酸0.8份、苏氨酸7份、精氨酸5份、脯氨酸5份、丙氨酸3份、缬氨酸3份、蛋氨酸2份和胱氨酸1份;
大鲵胶原蛋白肽的分子量范围为800~1200道尔顿。
实施例4
一、通过直肠给药达到抗衰老作用的注射剂
上述通过直肠给药达到抗衰老作用的注射剂由实施例3中的抗衰老组合物和生理盐水组成,注射剂中抗衰老组合物质量含量为25%。
二、制备方法
上述通过直肠给药达到抗衰老作用的注射剂的制备方法,该制备方法包括:
按照重量份称取各原料,将甘露醇和山梨酸至于生理盐水中混匀,得到混合溶液;
再将剩余原料置于混合溶液中,搅拌均匀,得到通过直肠给药达到抗衰老作用的注射剂。
实施例5
本实施例为一种通过直肠给药达到抗衰老作用的注射剂,该注射剂与实施例4中注射剂的组分基本相同,区别仅在于,将实施例4中采用的实施例3的抗衰老组合物替换为实施例1的抗衰老组合物;
上述通过直肠给药达到抗衰老作用的注射剂的制备方法同实施例4中的制备方法。
实施例6
本实施例为一种通过直肠给药达到抗衰老作用的注射剂,该注射剂与实施例4中的组分基本相同,区别仅在于,将实施例4中采用的实施例3的抗衰老组合物替换为实施例2的抗衰老组合物。
上述通过直肠给药达到抗衰老作用的注射剂的制备方法同实施例4中的制备方法。
实施例7
一、通过直肠给药达到抗衰老作用的栓剂
上述通过直肠给药达到抗衰老作用的栓剂由实施例3中的抗衰老组合物和药学上可接受的辅料组成,其中,
辅料为甘油明胶,且栓剂中辅料的质量含量为80%。
二、制备方法
上述通过直肠给药达到抗衰老作用的栓剂的制备方法,包括如下步骤:
将山梨酸和辅料按照比例混合加热;
将混合物冷却至40℃,再加入NMN、大鲵胶原蛋白肽、人参皂苷Rg1、SOD、复合氨基酸、甘露醇、hgh生长素和淫羊藿苷;
随后,进行灌模、冷却、成型、脱模和包装。
对照例1
本对照例为一种通过直肠给药达到抗衰老作用的注射剂,该注射剂与实施例4中的组分基本相同,区别仅在于将实施例3中的抗衰老组合物中大鲵胶原蛋白肽替换为同等分数的NMN;
上述通过直肠给药达到抗衰老作用的注射剂的制备方法同实施例4中的制备方法。
对照例2
本对照例为一种通过直肠给药达到抗衰老作用的注射剂,该注射剂与实施例4中的组分基本相同,区别仅在于将实施例3中的抗衰老组合物中复合氨基酸替换为同等分数的大鲵胶原蛋白肽;
上述通过直肠给药达到抗衰老作用的注射剂的制备方法同实施例4中的制备方法。
对照例3
本对照例为一种通过直肠给药达到抗衰老作用的注射剂,该注射剂与实施例4中的组分基本相同,区别仅在于将实施例3中的抗衰老组合物中淫羊藿苷替换为同等分数的人参皂苷Rg1;
上述通过直肠给药达到抗衰老作用的注射剂的制备方法同实施例4中的制备方法。
对照例4
本对照例为一种通过直肠给药达到抗衰老作用的注射剂,该注射剂与实施例4中的组分基本相同,区别仅在于将实施例3中的抗衰老组合物替换为如下组分:
NMN 12份、大鲵胶原蛋白肽2份、人参皂苷Rg1 3份、SOD 1份、复合氨基酸3份和淫羊藿苷1份;
上述通过直肠给药达到抗衰老作用的注射剂的制备方法同实施例4中的制备方法。
实验例
按照个人自愿,选择具有衰老症状:皮肤松弛、光泽暗黄、弹性下降、褶皱受试者100人,受试者年龄为29~80岁;随机将受试者分为5组,每组20人;
收集本发明实施例4和对照例1~4中制备得到的通过直肠给药达到抗衰老作用的注射剂,并将不同的注射剂分别对应每组受试者,并每天通过直肠进行给药,给药量为10ml/次,前三天每天给药一次,随后每周给药两次,持续给药20天;
实验过程中采用皮肤颜色测试仪Colorimeter CL400(广州沃克贸易有限公司)和皮肤皱纹测试仪Visioline VL650(北京金宏帆商贸有限责任公司)按照仪器的说明书分别对受试者的实验前和实验后的皮肤颜色和皮肤褶皱面积进行检测,并分别计算皮肤颜色和皮肤褶皱改善率,改善率=(实验后检测值-实验前检测值)/实验前检测值*100%;并计算各组平均值,计算结果如表1所示;
表1
组别 | 肤色(%) | 褶皱(%) |
实施例4 | 28.6 | 29.4 |
对照例1 | 23.7 | 18.3 |
对照例2 | 25.4 | 24.7 |
对照例3 | 24.1 | 22.8 |
对照例4 | 21.9 | 19.6 |
由表1可知:
通过对表1中的数据进行比较,本发明实施例4相对对照例1~4制备得到的注射剂具有更好的抗衰老作用,能够更好改善受试者的肤色和褶皱面积。
以下为采用实施例4注射剂的部分受试者案例:
受试者1
李某某,年龄80岁,女,存在肤色暗黄、褶皱较多、难以入睡、长期有腰痛感、走路乏力;通过直肠进行给药本发明实施例4中的注射剂,给药量为10ml次,前三天每天给药一次,随后每周给药两次,持续给药20天后,给药前后如图1所示,图中,左侧为给药前,右侧为给药后;
由图1可知,通过注射本发明注射剂,能够显著改善受试者肤色、褶皱,使得肤色白皙,褶皱减少,并了解到受试者入睡时间缩短1h左右,疼痛感显著降低,走路一口气可走1公里左右。
受试者2
王某,年龄58岁,女,存在全身皮肤发黄、有斑;通过直肠进行给药本发明实施例4中的注射剂,给药量为10ml次,前三天每天给药一次,随后每周给药两次,持续给药18天后,给药前后受试者的手部情况如图2所示,图中,左侧为给药前,右侧为给药后;
由图2可知,通过注射本发明注射剂,能够显著改善受试者肤色、降低斑点颜色。
受试者3
吴某某,年龄36岁,女,生完孩子7个月,给药前皮肤干燥,肤色发暗,由于抱孩子导致肌肉酸痛,看手机易疲倦,身体较胖,腰围(77cm),臀围(93),手臂(33cm);通过直肠进行给药本发明实施例4中的注射剂,给药量为10ml次,前三天每天给药一次,随后每周给药两次,持续给药25天后,给药前后受试者的腿部情况如图3所示,图中,左侧为给药前,右侧为给药后;
由图3可知,通过注射本发明注射剂,能够显著改善受试者皮肤干燥和肤色发暗的情况,同时腰围缩减至61cm,臀围瘦到89,手臂缩减至30cm,通过与受试者沟通,受试者的酸痛情况大大缓解,目前抱孩子已无肌肉酸痛,且看手机1h左右,眼睛无发干、流泪等不适症状。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围,其均应涵盖在本发明的权利要求和说明书的范围当中。
Claims (10)
1.一种抗衰老组合物,其特征在于,包括如下重量份的组分:
NMN 5~10份、大鲵胶原蛋白肽3~6份、人参皂苷Rg1 1~2份、SOD 2~3份、复合氨基酸1~2份、hgh生长素1~2份和淫羊藿苷2~3份。
2.根据权利要求1所述的抗衰老组合物,其特征在于,包括如下重量份的组分:
NMN 8份、大鲵胶原蛋白肽5份、人参皂苷Rg1 1.5份、SOD 2.5份、复合氨基酸1.5份、hgh生长素1.5份和淫羊藿苷2.5份。
3.根据权利要求1所述的抗衰老组合物,其特征在于,所述组分还包括山梨酸0.2~0.5份和甘露醇0.2~0.6份。
4.根据权利要求3所述的抗衰老组合物,其特征在于,所述大鲵胶原蛋白肽的分子量范围为800~1200道尔顿。
5.根据权利要求1或2所述的抗衰老组合物,其特征在于,每份所述复合氨基酸包括天冬氨酸6份、谷氨酸8份、丝氨酸0.1份、甘氨酸0.8份、苏氨酸7份、精氨酸5份、脯氨酸5份、丙氨酸3份、缬氨酸3份、蛋氨酸2份和胱氨酸1份。
6.如权利要求1~5任一所述的抗衰老组合物在制备抗衰老的药物、营养品或保健品中的应用。
7.一种通过直肠给药达到抗衰老作用的注射剂,其特征在于,包括权利要求1~5任一所述的抗衰老组合物和生理盐水,所述注射剂中抗衰老组合物质量含量为20~30%。
8.一种通过直肠给药达到抗衰老作用的栓剂,其特征在于,包括权利要求3或4所述的抗衰老组合物和药学上可接受的辅料;
所述辅料质量含量为70~80%。
9.根据权利要求8所述的栓剂,其特征在于,所述辅料为甘油明胶或聚乙二醇。
10.如权利要求8或9所述的栓剂的制备方法,其特征在于,包括如下步骤:
将山梨酸和辅料按照比例混合加热;
将混合物冷却至38~42℃,再加入NMN、大鲵胶原蛋白肽、人参皂苷Rg1、SOD、复合氨基酸、甘露醇、hgh生长素和淫羊藿苷;
随后,进行灌模、冷却、成型、脱模和包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010628553.7A CN111603552A (zh) | 2020-07-02 | 2020-07-02 | 一种抗衰老组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010628553.7A CN111603552A (zh) | 2020-07-02 | 2020-07-02 | 一种抗衰老组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111603552A true CN111603552A (zh) | 2020-09-01 |
Family
ID=72197268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010628553.7A Pending CN111603552A (zh) | 2020-07-02 | 2020-07-02 | 一种抗衰老组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111603552A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113491332A (zh) * | 2021-06-08 | 2021-10-12 | 杨宝亮 | 一种含有sod的全氨基酸营养素食品 |
CN114831894A (zh) * | 2021-12-17 | 2022-08-02 | 广西萌大夫生物技术有限公司 | 一种含nmn的氧化敏感纳米粒子及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1909895A (zh) * | 2004-01-08 | 2007-02-07 | 株式会社钟化 | 抗衰老组合物 |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
CN109045059A (zh) * | 2018-08-01 | 2018-12-21 | 泓博元生命科技(深圳)有限公司 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
CN110237118A (zh) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | 含烟酰胺单核苷酸的组合物在抗衰老药品/保健品的应用 |
CN111093397A (zh) * | 2017-09-14 | 2020-05-01 | 田中惠 | 一种抗衰老剂以及抗衰老方法 |
CN111172226A (zh) * | 2020-03-09 | 2020-05-19 | 中健智诊(重庆)生物研究院 | 用于肠道吸收的胶原蛋白肽及其提取方法和应用 |
-
2020
- 2020-07-02 CN CN202010628553.7A patent/CN111603552A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1909895A (zh) * | 2004-01-08 | 2007-02-07 | 株式会社钟化 | 抗衰老组合物 |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
CN111093397A (zh) * | 2017-09-14 | 2020-05-01 | 田中惠 | 一种抗衰老剂以及抗衰老方法 |
CN109045059A (zh) * | 2018-08-01 | 2018-12-21 | 泓博元生命科技(深圳)有限公司 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
CN110237118A (zh) * | 2019-06-06 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | 含烟酰胺单核苷酸的组合物在抗衰老药品/保健品的应用 |
CN111172226A (zh) * | 2020-03-09 | 2020-05-19 | 中健智诊(重庆)生物研究院 | 用于肠道吸收的胶原蛋白肽及其提取方法和应用 |
Non-Patent Citations (4)
Title |
---|
李芬: "HGH:21世纪人类抗衰老首选", 《健康顾问》 * |
杨逸,等: "人参皂苷Rg1药理活性的研究进展", 《时珍国医国药》 * |
纪昕: "淫羊藿苷免疫调节作用的研究进展", 《河北医药》 * |
谭锐志: "复合氨基酸对延缓衰老的功效", 《2013年国际氨基酸产业发展高峰论坛》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113491332A (zh) * | 2021-06-08 | 2021-10-12 | 杨宝亮 | 一种含有sod的全氨基酸营养素食品 |
CN114831894A (zh) * | 2021-12-17 | 2022-08-02 | 广西萌大夫生物技术有限公司 | 一种含nmn的氧化敏感纳米粒子及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111658818B (zh) | 一种医用修复敷料及其应用 | |
KR101132392B1 (ko) | 발효 태반 조성물 및 그 용도 | |
JP2018070644A (ja) | 天然ビタミンcとコラーゲンペプチドの組成物及びその製造方法 | |
CN111603552A (zh) | 一种抗衰老组合物及其应用 | |
JPWO2005077349A1 (ja) | ヒトβディフェンシン産生促進剤 | |
CN111419784A (zh) | 一种含nmn的抗皱眼霜及其制备方法和应用 | |
CN111407685A (zh) | 重组纤连-类人胶原蛋白抗衰组合物及其制备方法 | |
CN111297727A (zh) | 一种美塑治疗组合物及其应用 | |
KR101705938B1 (ko) | 피부 콜라겐 생성 촉진제 | |
WO2014203885A1 (ja) | コラーゲン産生促進剤 | |
CN109248138A (zh) | 一种抗皱化妆品组合物及其制备方法 | |
CN106389139A (zh) | 一种祛痘消痕护肤多功能制剂及其制备方法 | |
CN106727115A (zh) | 一种用于增生性疤痕修复的护肤霜及其制备方法 | |
CN116143873A (zh) | 活性肽及其用于制备抗皮肤老化的药物或者化妆品中的应用 | |
CN110368347A (zh) | 一种抗衰修复双层双色精华素及其制备方法 | |
JP5955499B2 (ja) | 皮膚コラーゲン産生促進剤 | |
KR102475936B1 (ko) | 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물 | |
KR101305274B1 (ko) | 콜라겐 합성 촉진용 조성물 | |
KR101753874B1 (ko) | 데카펩타이드를 유효성분으로 포함하는 화장료 조성물 | |
KR101218898B1 (ko) | 콜라겐 합성 촉진용 조성물 | |
WO2010043073A1 (zh) | 一种胶原多肽及其制备方法和应用 | |
CN115737472A (zh) | 含重组胶原蛋白的可即时减轻表情纹的组合物及制备方法 | |
CN114805601A (zh) | 一种多肽类似物在抗皱抗衰老中的应用 | |
WO2018120401A1 (zh) | 一种化妆品组合物 | |
CN107375012A (zh) | 一种皮肤屏障修复组合物及制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |